Silo Pharma shares are trading higher after the company announced its submission of a pre-Investigational New Drug briefing package and meeting request to the FDA for SPC-15 as a treatment for PTSD and anxiety.
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma shares are trading higher following the company's submission of a pre-Investigational New Drug briefing package and meeting request to the FDA for SPC-15, aimed at treating PTSD and anxiety.
June 04, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma shares are trading higher after the company announced its submission of a pre-IND briefing package and meeting request to the FDA for SPC-15 as a treatment for PTSD and anxiety.
The submission of a pre-IND briefing package to the FDA is a significant step in the drug development process. This news likely boosts investor confidence in Silo Pharma's potential to bring SPC-15 to market, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100